“Without validated measurement infrastructure, it is impossible to rank polymers by harm or to confirm that interventions are working.”
— Dr. Charlotte Steenblock, co-author

Microplastics Found in Human Brain Tissue at Rising Levels, New Review Warns

A new scientific review, published on May 5, 2026, in the inaugural issue of the journal Brain Health, synthesizes evidence on the accumulation of microplastics and nanoplastics in human brain tissue. The authors—researchers from the USA, Germany, and Canada—argue that the presence of these particles in the brain constitutes a health concern requiring validated measurement methods and scalable removal strategies.

Key Findings on Human Tissue

The Perspective reviews data from a study of decedent human brain tissue samples collected between 2016 and 2024. Microplastic concentrations in the brain were found to be 7–30 times higher than in the liver or kidney. Over the eight-year study period, the cumulative burden in the brain increased by approximately 50%.

The highest levels were observed in donors with dementia. The dominant polymer identified was polyethylene, primarily in the form of nanoscale shards.

Cardiovascular and Animal Study Evidence

The article references a study by Marfella et al., which identified microplastics and nanoplastics in carotid atheromatous plaques. Patients with microplastics in these plaques had a fourfold increase in the composite risk of myocardial infarction, stroke, or death over a 34-week period.

In animal models, the authors cite research by Kopatz et al., which found that polystyrene nanoparticles crossed the blood-brain barrier in mice within two hours of oral administration. Larger particles did not cross the barrier.

Ultra-Processed Foods as an Exposure Vector

The Perspective identifies ultra-processed foods (NOVA Group 4) as a significant vector for microplastic exposure. These foods supply over 50% of calories in the average U.S. diet.

The review notes that, independent of their microplastic content, high consumption of these foods has been linked in prospective cohort studies to an increased risk of depression, anxiety, cognitive decline, stroke, and dementia.

Potential Intervention and Policy Context

The article discusses therapeutic apheresis as a potential intervention. This established clinical modality has been used to extract material consistent with microplastic particles from human plasma. The authors note that polymer-specific quantification methods are needed to confirm the efficacy of removal.

In April 2026, the U.S. Advanced Research Projects Agency for Health (ARPA-H) launched the STOMP (Systematic Targeting Of MicroPlastics) program. The program aims to develop measurement standards, elucidate biological mechanisms, and translate findings into clinical removal strategies.

Vulnerable Populations and Measurement Gaps

The review notes that microplastics have been found in human placenta, indicating fetal exposure. It identifies children and patients with cerebrovascular or neurodegenerative disease as populations of particular concern.

The authors emphasize a critical need for standardized, validated measurement infrastructure. As Dr. Steenblock stated, without such tools, it is impossible to rank polymers by harm or to confirm that interventions are working.